<div><div></div><div><span><p><span>TuHURA Biosciences, Inc. reported first-quarter 2026 results showing no product revenue and a wider net loss versus the prior-year quarter as the company ramps clinical and R&amp;D programs tied to its immunotherapy pipeline.</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Revenue: $0 for Q1 2026 and Q1 2025 (no product revenue reported).</span></li><li><span>Net income: Net loss attributable to common stockholders of $(7.54M) for Q1 2026 versus net loss $(6.67M) for Q1 2025 (≈ $(0.87M) change YoY).</span></li><li><span>Diluted EPS: $(0.13) for Q1 2026 versus $(0.15) for Q1 2025 (basic and diluted; YoY improvement).</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Clinical milestone: Began a randomized, placebo-controlled Phase 3 trial of IFx-2.0 with pembrolizumab in first-line metastatic Merkel cell carcinoma (initiated June 2025).</span></li><li><span>Pipeline expansion: Completed the acquisition of Kineta and added TBS-2025, a VISTA inhibitor, with plans for a randomized Phase 2 in mutNPM1 AML in combination with a menin inhibitor.</span></li><li><span>R&amp;D focus shift: Increased headcount and R&amp;D spend toward IFx-2.0 and TBS-2025 and discontinued advancement of IFx-3.0.</span></li><li><span>Capital and liquidity actions: Launched a $50M at-the-market program, a $50M revolving credit facility, and completed registered direct/private placements to fund planned development.</span></li><li><span>Operational scale-up: Outsourced clinical operations to CROs, secured third-party manufacturing, and expanded regulatory and commercial readiness activities.</span></li></ul><p><span>Original SEC Filing: </span>TuHURA Biosciences, Inc./NV [ HURA ] - 10-Q - May. 15, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

HURA

SBIO

LABU

<p>TuHURA Biosciences, Inc. reported Q1 2026 results with $0 revenue and a net loss of $(7.54M), compared to $(6.67M) in Q1 2025. The company initiated a Phase 3 trial for IFx-2.0 and expanded its pipeline with the acquisition of Kineta. They launched a $50M market program and secured funding for development. R&D efforts are focused on IFx-2.0 and TBS-2025, while discontinuing IFx-3.0.</p>

TradingView

TuHURA Biosciences

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

TuHURA Biosciences, Inc. 1Q 2026: Revenue $0 Net loss $(7.54M), EPS $(0.13) — 10-Q Summary